Unjha Formulations P/E Ratio
Current P/E Ratio
26.24
High Valuation
High - Growth expectations or overvalued
Unjha Formulations (UNJHAFOR) P/E ratio is 26.24 (High), EPS (TTM) ₹1.57, current price ₹27.49 on BSE — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see Unjha Formulations stock price NSE.
Current Valuation Metrics
P/E Ratio
26.24
Current Price
₹27.49
EPS (TTM)
₹1.57
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
55.62
Sector Median
31.02
Sector Rank
#11 of 195
Sector Percentile
5.6%
UNJHAFOR P/E Ratio — Valuation Signal & Historical Context
Unjha Formulations P/E 26.24 — signal: Overvalued. See UNJHAFOR book value comparison to compare market price against book value per share.
- Stock appears overvalued with PE of 26.24, suggesting caution for new investments
- Trading at discount to sector average PE of 55.62
UNJHAFOR vs Healthcare Peers — P/E Ratio Comparison
Unjha Formulations P/E 26.24 vs Healthcare average 55.62, median 31.02 — range 2.86–712.0.
Sector Average
55.62
Sector Median
31.02
Lowest P/E
2.86
Highest P/E
712.0
Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.29 | ₹53 | Low |
| Colinz Laboratories | COLINZ | 3.6 | ₹10 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.05 | ₹6,404 | Low |
| Sunrest Lifescience | SUNREST | 4.08 | ₹65 | Low |
| Shelter Pharma | SHELTER | 4.85 | ₹44 | Low |
| GKB Ophthalmics | GKB | 5.94 | ₹33 | Low |
| JFL Life Sciences | JFLLIFE | 6.44 | ₹86 | Low |
| Dipna Pharmachem | DPL | 6.52 | ₹18 | Low |
| Royal Sense | ROYAL | 7.11 | ₹51 | Low |